SRRK

Insider Trades

Name	Value	Action	Price	Current Price
Hallal DavidDirector, Officer: Chief Executive Officer $1.5M30.6k shares SellApr 16, 2026 $49.57 --
Vaishnaw AkshayDirector, Officer: President Of R&D $607k12.2k shares SellApr 16, 2026 $49.57 --
Sinha VikasChief Financial Officer $516k10.4k shares SellApr 16, 2026 $49.57 --
Woods KeithChief Operating Officer $507k10.2k shares SellApr 16, 2026 $49.57 --
Qatanani MoCHIEF SCIENTIFIC OFFICER $349k7.4k shares SellFeb 23, 2026 $46.94 --
Qatanani MoCHIEF SCIENTIFIC OFFICER $41k857 shares SellFeb 23, 2026 $47.86 --

News

seekingalpha.comScholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9

businesswire.comScholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conferencebusinesswire.comMay 26

businesswire.comScholar Rock to Present at the 2026 Jefferies Global Healthcare Conferencebusinesswire.comMay 20

247wallst.comThree Biotechs That Are Top Takeover Targets247wallst.comMay 18

businesswire.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.comMay 15

Trade SRRK

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

CEO: David L. Hallal
IPO Date: May 25, 2018

Market Data

Open: $45.99
High: $47.71
Low: $44.03
Volume: 1.5M
52W High: $52.19
52W Low: $27.07

Valuation

Market Cap: $5.3B
Enterprise Value: $5.1B

Financials

Free Cash Flow: $-301M
Revenue: $0
Net Income: $-378M
Cash: $324M
Debt: $109M

Events

EarningsAug 5

EPS est. -0.84